Scarica l'app Stockscreener
2.03
7.98%
0.15
Dopo l'orario di chiusura:
2.05
0.02
+0.99%
Precedente Chiudi:
$1.88
Aprire:
$1.83
Volume 24 ore:
71,631
Relative Volume:
1.74
Capitalizzazione di mercato:
$2.64M
Reddito:
-
Utile/perdita netta:
$-11.28M
Rapporto P/E:
-0.6744
EPS:
-3.01
Flusso di cassa netto:
$-9.78M
1 W Prestazione:
-11.35%
1M Prestazione:
-55.87%
6M Prestazione:
-23.88%
1 anno Prestazione:
-82.05%
Intervallo 1D:
$1.76
$2.12
Intervallo di 1 settimana:
$1.70
$2.3105
Portata 52W:
$1.70
$14.67
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Nome
Ensysce Biosciences Inc
Settore
Industria
Telefono
(858) 263-4196
Indirizzo
7946 IVANHOE AVENUE, LA JOLLA
Confronta ENSC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
2.03 | 2.64M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.22 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.18 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.94 | 35.43B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.77 | 30.77B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
96.52 | 23.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ensysce Biosciences Inc Borsa (ENSC) Ultime notizie
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ENSC stock touches 52-week low at $2.11 amid market challenges - Investing.com
After-Hour Gains For Ensysce Biosciences (ENSC) Signal Renewed Interest - Stocks Telegraph
Ensysce Biosciences corrects SEC filing omission By Investing.com - Investing.com South Africa
Ensysce Biosciences corrects SEC filing omission - Investing.com
Ensysce Biosciences raises $1.1 million in stock sale By Investing.com - Investing.com South Africa
Ensysce Biosciences raises $1.1 million in stock sale - Investing.com
Ensysce Raises Fresh Capital: Strategic $1.1M Investment Powers Next-Gen Pain Drug Pipeline - Stock Titan
Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting - ACCESS Newswire
(ENSC) On The My Stocks Page - news.stocktradersdaily.com
Ensysce Biosciences Advances in Opioid Innovation - TipRanks
Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga
Revolutionary Opioid Safety Technology Takes Center Stage at PAINWeek 2025 - StockTitan
How the (ENSC) price action is used to our Advantage - news.stocktradersdaily.com
Ensysce Biosciences (ENSC) Projected to Post Earnings on Friday - Defense World
Zacks Small Cap Issues Negative Forecast for ENSC Earnings - Defense World
Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) - EIN News
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
When Will Ensysce Biosciences, Inc. (NASDAQ:ENSC) Breakeven? - Simply Wall St
Ensysce Biosciences Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Ensysce Biosciences, Inc. SEC 10-K Report - TradingView
Ensysce Biosciences Narrows Losses to $8M, Secures FDA Breakthrough Status - StockTitan
(ENSC) Long Term Investment Analysis - Stock Traders Daily
Ensysce Biosciences to Present Pain Management Innovations at ROTH Conference - StockTitan
Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids - Marketscreener.com
Ensysce Biosciences Releases Updated Investor Presentation Available Via Investor Relations Website - ACCESS Newswire
Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results - ACCESS Newswire
Ensysce Biosciences Regains Compliance with Nasdaq - ACCESS Newswire
Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering - ACCESS Newswire
How To Trade (ENSC) - Stock Traders Daily
Revolutionary Pain Management: This New Opioid Actually Prevents Overdose - StockTitan
When Can We Expect A Profit From Ensysce Biosciences, Inc. (NASDAQ:ENSC)? - Yahoo Finance
Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call - ACCESS Newswire
Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic - ACCESS Newswire
Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium - ACCESS Newswire
Ensysce Biosciences Receives Positive Nasdaq Listing Determination - ACCESS Newswire
Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update Call - ACCESS Newswire
Ensysce Biosciences Chief Medical Officer to Chair the 17th Annual Pain Therapeutics Summit - ACCESS Newswire
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate - ACCESS Newswire
Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection - ACCESS Newswire
Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR - NEWSnet
Ensysce reports overdose protection in drug trial - Investing.com
Ensysce's PF614-MPAR Shows Breakthrough Overdose Protection in Phase 1b Opioid Trial - StockTitan
Biotech Steals The Show Following $14 Million Grant Announcement - MSN
Ensysce's Breakthrough Pain Drug Gets FDA Special Status; Secures $23.7M Funding Boost - StockTitan
Ensysce Biosciences Inc Azioni (ENSC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):